News | November 06, 2017 | Dave Fornell

No Major Differences Between PCI vs. CABG vs. Hybrid Revascularization in HREVS Study

HREVS study principal investigator Vladimir Ganyukov, M.D., Ph.D., head of interventional cardiology, State Scientific Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia, at TCT 2017.

Study principal investigator Vladimir Ganyukov, M.D., Ph.D., head of interventional cardiology, State Scientific Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia, explaining the HREVS trial results at TCT 2017.


November 6, 2017 — In the Hybrid REvascularization Versus Standards (HREVS) study that evaluated three different revascularization strategies, there was no major difference between the use of coronary artery bypass grafts (CABG), drug-eluting stent percutaneous coronary interventions (DES-PCI) or hybrid coronary revascularization (HCR) using a LIMA-LAD graft plus DES-PCI for the remaining vessels. The data from the trial was presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. 

Today, revascularization in multivessel coronary artery disease (MV-CAD) is achieved mainly through CABG or DES-PCI. A less-evidenced approach is the hybrid coronary revascularization (HCR). The aim of the study was to compare in a randomized trial the current guideline accepted revascularization strategy for multi-vessel coronary artery disease versus a hybrid revascularization strategy.  The single center study included 154 patients who agreed to be randomized to one of the three revascularization methods (CABG, DES-PCI or HCR). The study was powered for a primary endpoint of residual myocardial ischemia at 12 months. 

At 30 days, there were no significant differences. There was 9.6 percent (n=5) conversion to CABG in the hybrid group and higher rate of bleeding with surgery, which was expected, said study principal investigator Vladimir Ganyukov, M.D., Ph.D., head of interventional cardiology, State Scientific Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.

He said PCI was associated with the shortest hospital stay and sick-leave duration.

Major adverse events within 30 days were similar in terms of MACCE and its components. In the HCR group there were five patients (9.8 percent) who required conversion to conventional on-pump CABG with a median sternotomy either for surgical technical reasons (n=2) or due to hemodynamic instability following LIMA-LAD grafting in the absence of other lesion(s) revascularization (n=3). The HCR group was associated with a lower bleeding (for BARC 3-4) than CABG. 

At 12 months, there were no statistically significant difference s in residual ischemia. The primary study end-point of non-inferiority was met.

Target vessel of graft failure were similar across the study arms. The secondary endpoint and events at one year were comparable in the three groups. The major adverse coronary and cerebral event (MACCE) rate at 12 months was 12 percent for CABG, versus 13.4 for HCR, and 13.2 percent (p=0.83). Target vessel or graft failure rate at 12 months was 12 percent for CABG, 11.5 HCR and 11.3 for PCI (p>0.05). 

There was MACCE-free survival at 12 months was nearly identical for all three arms. 

 

Related Content

TCT 2017 Late-breaking Clinical Trial Presentations

 


Related Content

News | Cardiovascular Surgery

March 15, 2023 — Researchers at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine published ...

Home March 15, 2023
Home
News | Cardiovascular Surgery

February 7, 2023 — A scientific session devoted to identifying and closing gaps in health care took place January 21 ...

Home February 07, 2023
Home
News | Cardiovascular Surgery

January 31, 2023 — Serotonin can impact the mitral valve of the heart and potentially accelerate a cardiac condition ...

Home January 31, 2023
Home
News | Cardiovascular Surgery

December 30, 2022 — Azmi Atiya, MD, an established and highly respected cardiothoracic surgeon in the San Fernando ...

Home December 30, 2022
Home
News | Cardiovascular Surgery

December 21, 2022 — The Smidt Heart Institute at Cedars-Sinai is again expanding its geographic reach and surgical ...

Home December 21, 2022
Home
News | Cardiovascular Surgery

October 24, 2022 The Smidt Heart Institute at Cedars-Sinai has selected leading vascular surgeon Donald Baril, MD, as ...

Home October 24, 2022
Home
News | Cardiovascular Surgery

October 17, 2022 — Allegheny Health Network’s (AHN) Cardiovascular Institute announced the expansion of its nationally ...

Home October 17, 2022
Home
News | Cardiovascular Surgery

September 7, 2022 — Nuwellis, Inc., a commercial-stage company focused on transforming the lives of people with fluid ...

Home September 07, 2022
Home
News | Cardiovascular Surgery

August 15, 2022 — Unnatural, direct connections between arteries and veins, like an access point for kidney dialysis and ...

Home August 15, 2022
Home
News | Cardiovascular Surgery

August 12, 2022 — Atrium Health Pineville has earned a distinguished three-star rating – the highest possible ...

Home August 12, 2022
Home
Subscribe Now